ADC Therapeutics SA Net Income
| ADCT Stock | USD 3.90 0.29 8.03% |
As of the 3rd of February, ADC Therapeutics owns the variance of 22.02, and Market Risk Adjusted Performance of (0.07). ADC Therapeutics SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.
ADC Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.6312 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -142.1 M | -149.2 M | |
| Net Loss | -140.2 M | -147.2 M | |
| Net Loss | -142.1 M | -149.2 M | |
| Net Loss | (1.87) | (1.96) | |
| Net Income Per E B T | 0.90 | 0.82 |
ADC | Net Income | Build AI portfolio with ADC Stock |
The evolution of Net Income for ADC Therapeutics SA provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how ADC Therapeutics compares to historical norms and industry peers.
Latest ADC Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of ADC Therapeutics SA over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ADC Therapeutics financial statement analysis. It represents the amount of money remaining after all of ADC Therapeutics SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ADC Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (157.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ADC Net Income Regression Statistics
| Arithmetic Mean | (134,179,110) | |
| Coefficient Of Variation | (41.86) | |
| Mean Deviation | 45,095,894 | |
| Median | (116,484,000) | |
| Standard Deviation | 56,172,850 | |
| Sample Variance | 3155.4T | |
| Range | 156.4M | |
| R-Value | (0.67) | |
| Mean Square Error | 1867.9T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (7,420,854) | |
| Total Sum of Squares | 50486.2T |
ADC Net Income History
Other Fundumenentals of ADC Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ADC Therapeutics Net Income component correlations
ADC Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Net Income. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Communications Equipment market expansion? Will ADC introduce new products? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
Understanding ADC Therapeutics requires distinguishing between market price and book value, where the latter reflects ADC's accounting equity. The concept of intrinsic value—what ADC Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push ADC Therapeutics' price substantially above or below its fundamental value.
Understanding that ADC Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADC Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ADC Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ADC Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ADC Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ADC Therapeutics.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in ADC Therapeutics on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding ADC Therapeutics SA or generate 0.0% return on investment in ADC Therapeutics over 90 days. ADC Therapeutics is related to or competes with Omeros, Neumora Therapeutics, RAPT Therapeutics, Autolus Therapeutics, Alumis, Bicycle Therapeutics, and Lexicon Pharmaceuticals. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering ... More
ADC Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ADC Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ADC Therapeutics SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 22.84 | |||
| Value At Risk | (7.06) | |||
| Potential Upside | 8.49 |
ADC Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADC Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ADC Therapeutics' standard deviation. In reality, there are many statistical measures that can use ADC Therapeutics historical prices to predict the future ADC Therapeutics' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (0.08) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ADC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ADC Therapeutics February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 3.33 | |||
| Coefficient Of Variation | (5,567) | |||
| Standard Deviation | 4.69 | |||
| Variance | 22.02 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 22.84 | |||
| Value At Risk | (7.06) | |||
| Potential Upside | 8.49 | |||
| Skewness | 0.105 | |||
| Kurtosis | 1.33 |
ADC Therapeutics Backtested Returns
Currently, ADC Therapeutics SA is risky. ADC Therapeutics retains Efficiency (Sharpe Ratio) of 0.0147, which signifies that the company had a 0.0147 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for ADC Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm ADC Therapeutics' market risk adjusted performance of (0.07), and Variance of 22.02 to double-check if the risk estimate we provide is consistent with the expected return of 0.0704%. ADC Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of 1.13, which signifies a somewhat significant risk relative to the market. ADC Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, ADC Therapeutics is expected to follow. ADC Therapeutics at this moment owns a risk of 4.78%. Please confirm ADC Therapeutics SA potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if ADC Therapeutics SA will be following its current price history.
Auto-correlation | 0.04 |
Virtually no predictability
ADC Therapeutics SA has virtually no predictability. Overlapping area represents the amount of predictability between ADC Therapeutics time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ADC Therapeutics price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current ADC Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ADC Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ADC Therapeutics SA reported net income of (157.85 Million). This is 146.25% lower than that of the Communications Equipment sector and significantly lower than that of the Information Technology industry. The net income for all United States stocks is 127.64% higher than that of the company.
ADC Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.ADC Therapeutics is currently under evaluation in net income category among its peers.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.6B | 300.1M | 135.6M | 193.3M | 222.4M | 211.2M | |
| Enterprise Value | 1.2B | 103.5M | (18.6M) | 65.5M | 75.3M | 71.5M |
ADC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ADC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ADC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
ADC Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in ADC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ADC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADC Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 1.2 M | Geode Capital Management, Llc | 2025-06-30 | 858.8 K | Woodline Partners Lp | 2025-06-30 | 842.9 K | Ubs Group Ag | 2025-06-30 | 827.6 K | Blue Owl Capital Holdings Lp | 2025-06-30 | 733.6 K | Vantage Consulting Group Inc. | 2025-06-30 | 683 K | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 597.8 K | Vanguard Group Inc | 2025-06-30 | 560.5 K | Northern Trust Corp | 2025-06-30 | 426.9 K | Redmile Group, Llc | 2025-06-30 | 15.7 M | Prosight Management, Lp | 2025-06-30 | 10.5 M |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (2.22) % | ||||
| Operating Margin | (1.86) % | ||||
| Current Valuation | 348.31 M | ||||
| Shares Outstanding | 123.88 M | ||||
| Shares Owned By Insiders | 13.76 % | ||||
| Shares Owned By Institutions | 59.09 % | ||||
| Number Of Shares Shorted | 3.83 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 5.95 X | ||||
| Revenue | 70.84 M | ||||
| Gross Profit | (43.18 M) | ||||
| EBITDA | (102.65 M) | ||||
| Net Income | (157.85 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 123 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (2.12) X | ||||
| Cash Flow From Operations | (123.83 M) | ||||
| Short Ratio | 3.87 X | ||||
| Earnings Per Share | (1.35) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 263 | ||||
| Beta | 1.96 | ||||
| Market Capitalization | 447.2 M | ||||
| Total Asset | 321.98 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 226.92 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 321.98 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.